title: Epigenetic Modifications with DZNep, NaBu and SAHA in Luminal and Mesenchymal-like Breast Cancer Subtype Cells.
abstract: OBJECTIVE
  Numerous studies have shown that breast cancer and epigenetic mechanisms have a very powerful interactive relation. The MCF7 cell line, representative of luminal subtype and the MDA-MB 231 cell line representative of mesenchymal-like subtype were treated respectively with a Histone Methyl Transferase Inhibitors (HMTi), 3-Deazaneplanocin hydrochloride (DZNep), two histone deacetylase inhibitors (HDACi), sodium butyrate (NaBu), and suberoylanilide hydroxamic acid (SAHA) for 48 h.
  
  
  METHODS
  Chromatin immunoprecipitation (ChIP) was used to observe HDACis (SAHA and NaBu) and HMTi (DZNep) impact on histones and more specifically on H3K27me3, H3K9ac and H3K4ac marks with Q-PCR analysis of BRCA1, SRC3 and P300 genes. Furthermore, the HDACi and HMTi effects on mRNA and protein expression of BRCA1, SRC3 and P300 genes were checked. In addition, statistical analyses were used.
  
  
  RESULTS
  In the MCF7 luminal subtype with positive ER, H3k4ac was significantly increased on BRCA1 with SAHA. On the contrary, in the MDA-MB 231 breast cancer cell line, representative of mesenchymal-like subtype with negative estrogen receptor, HDACis had no effect. Also, DZNEP decreased significantly H3K27me3 on BRCA1 in MDA-MB 231. Besides, on SRC3, a significant increase for H3K4ac was obtained in MCF7 treated with SAHA. And DZNEP had no effect in MCF7. Also, in MDA-MB 231 treated with DZNEP, H3K27me3 significantly decreased on SRC3 while H3K4ac was significantly increased in MDA-MB-231 treated with SAHA or NaBu for P300.
  
  
  CONCLUSIONS
  Luminal and mesenchymal-like breast cancer subtype cell lines seemed to act differently to HDACis (SAHA and NaBu) or HMTi (DZNEP) treatments.
authors.affiliation: Department of Oncogenetics, Centre Jean Perrin, CBRV, Clermont-Ferrand, France EA 4677 "ERTICA", University of Auvergne, Clermont-Ferrand, France.
authors.forename: Aslihan
authors.initials: A
authors.lastname: Dagdemir
authors.affiliation: Department of Oncogenetics, Centre Jean Perrin, CBRV, Clermont-Ferrand, France EA 4677 "ERTICA", University of Auvergne, Clermont-Ferrand, France.
authors.forename: Gaëlle
authors.initials: G
authors.lastname: Judes
authors.affiliation: University Blaise Pascal, Institute Pascal UMR 6602 CNRS/UBP, Aubière, France.
authors.forename: André
authors.initials: A
authors.lastname: Lebert
authors.affiliation: Department of Oncogenetics, Centre Jean Perrin, CBRV, Clermont-Ferrand, France EA 4677 "ERTICA", University of Auvergne, Clermont-Ferrand, France.
authors.forename: Maureen
authors.initials: M
authors.lastname: Echegut
authors.affiliation: Department of Oncogenetics, Centre Jean Perrin, CBRV, Clermont-Ferrand, France EA 4677 "ERTICA", University of Auvergne, Clermont-Ferrand, France Department of Toxicology, Faculty of Pharmacy, Marmara University, Istanbul, Turkey.
authors.forename: Seher
authors.initials: S
authors.lastname: Karsli-Ceppioglu
authors.affiliation: Department of Oncogenetics, Centre Jean Perrin, CBRV, Clermont-Ferrand, France EA 4677 "ERTICA", University of Auvergne, Clermont-Ferrand, France.
authors.forename: Khaldoun
authors.initials: K
authors.lastname: Rifaï
authors.affiliation: Department of Oncogenetics, Centre Jean Perrin, CBRV, Clermont-Ferrand, France EA 4677 "ERTICA", University of Auvergne, Clermont-Ferrand, France.
authors.forename: Marine
authors.initials: M
authors.lastname: Daures
authors.affiliation: Department of Oncogenetics, Centre Jean Perrin, CBRV, Clermont-Ferrand, France EA 4677 "ERTICA", University of Auvergne, Clermont-Ferrand, France.
authors.forename: Marjolaine
authors.initials: M
authors.lastname: Ngollo
authors.affiliation: Department of Oncogenetics, Centre Jean Perrin, CBRV, Clermont-Ferrand, France EA 4677 "ERTICA", University of Auvergne, Clermont-Ferrand, France.
authors.forename: Lucas
authors.initials: L
authors.lastname: Dubois
authors.affiliation: EA 4677 "ERTICA", University of Auvergne, Clermont-Ferrand, France Department of Biopathology, Centre Jean Perrin, Clermont-Ferrand, France.
authors.forename: Frédérique
authors.initials: F
authors.lastname: Penault-Llorca
authors.affiliation: Department of Oncogenetics, Centre Jean Perrin, CBRV, Clermont-Ferrand, France EA 4677 "ERTICA", University of Auvergne, Clermont-Ferrand, France.
authors.forename: Yves-Jean
authors.initials: YJ
authors.lastname: Bignon
authors.affiliation: Department of Oncogenetics, Centre Jean Perrin, CBRV, Clermont-Ferrand, France EA 4677 "ERTICA", University of Auvergne, Clermont-Ferrand, France dominique.gallon-bernard@clermont.unicancer.fr.
authors.forename: Dominique
authors.initials: D
authors.lastname: Bernard-Gallon
mesh_terms: D000241:Adenosine / Q000031:analogs & derivatives* / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000494:pharmacology*; D019313:BRCA1 Protein / Q000235:genetics / Q000378:metabolism; D001943:Breast Neoplasms / Q000235:genetics* / Q000473:pathology*; D045744:Cell Line, Tumor; D050881:E1A-Associated p300 Protein / Q000235:genetics / Q000378:metabolism; D044127:Epigenesis, Genetic / Q000187:drug effects*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects*; D056572:Histone Deacetylase Inhibitors / Q000494:pharmacology*; D006657:Histones / Q000378:metabolism; D006801:Humans; D056921:Nuclear Receptor Coactivator 3 / Q000235:genetics / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D019313:BRCA1 Protein; C492913:BRCA1 protein, human; D056572:Histone Deacetylase Inhibitors; D006657:Histones; C048460:3-deazaneplanocin; D050881:E1A-Associated p300 Protein; C538866:NCOA3 protein, human; D056921:Nuclear Receptor Coactivator 3; D000241:Adenosine
keywords: Breast cancer cell lines; histone deacetylase inhibitor; histone methyl transferase inhibitor